epcoritamab-bysp
View Patient InformationA bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab-bysp contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab-bysp binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.
Synonym: | anti-CD20/CD3 bispecific antibody GEN3013 DuoBody-CD3xCD20 epcoritamab |
---|---|
US brand name: | Epkinly |
Code name: | GEN 3013 GEN-3013 GEN3013 |